• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Aethlon CEO Appointed Co-Chairman of Bioterrorism/Chemical and Nuclear Security Task Force

Posted on: Thursday, 10 November 2005, 09:00 CST

Aethlon Medical, Inc. (OTCBB:AEMD) announced that its Chairman and CEO, James A. Joyce, has been appointed Co-Chairman of the Bioterrorism/Chemical and Nuclear Security Task Force of the Homeland Security Industries Association (HSIA).

"I am honored to have the opportunity to participate in the HSIA's efforts to evolve and influence policies to protect our citizens," stated Mr. Joyce. "I also hope that my participation will increase the visibility of our endeavors at Aethlon among industry colleagues," concluded Joyce. Mr. Joyce has been an active participant in the emerging biodefense industry. He recently testified before Congress on issues related to Project BioShield legislation and the deployment of the Aethlon Hemopurifier(TM) as a countermeasure against biological weapons. His efforts have been instrumental in expanding the definition of bioweapon treatment countermeasure in new legislation to include medical devices, such as the Hemopurifier. Most recently, he served on the Project BioShield panel at the Federal Biodefense Research Conference in Washington, D.C.

About The Homeland Security Industries Association

The Homeland Security Industries Association (HSIA) is a non-profit corporation established in July of 2002. It has over 200 members. The mission of the HSIA is to provide a mechanism for government and the private sector to coordinate on a wide range of homeland security issues. More information can be found at www.hsianet.org.

About Aethlon Medical

Aethlon Medical is pioneering the development of immunotherapeutic devices able to mimic the immune response of clearing viruses and viral toxins from circulation. The Company's lead product, the Hemopurifier(TM), converges the established principals of hemodialysis and affinity chromatography with the discovery of compounds that effectively adhere to the surface of a multiple envelope viruses. The Hemopurifier(TM) is targeted to treat acute and chronic infectious diseases, including drug and vaccine resistant Biological Weapons, the Human Immunodeficiency Virus (HIV) and the Hepatitis-C Virus (HCV). The Company has an experienced management team, which receives support and guidance from globally recognized science and regulatory advisors representing the infectious disease, biowarfare and dialysis industries. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

Source: Business Wire

More News in this Category